Literature DB >> 17350669

Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.

Shuji Ogino1, Takako Kawasaki, Akiyo Ogawa, Gregory J Kirkner, Massimo Loda, Charles S Fuchs.   

Abstract

Overexpression of fatty acid synthase (FASN), a key enzyme for de novo lipogenesis, is observed in many cancers including colorectal cancer and is associated with poor clinical outcomes. Cellular FASN expression is physiologically upregulated in a state of energy excess. Obesity and excess energy balance have been known to be risk factors for colorectal cancer. High degree of microsatellite instability (MSI-H) is a distinct phenotype in colorectal cancer, associated with CpG island methylator phenotype (CIMP). Previous data suggest that obesity or altered energy balance may potentially modify risks for MSI-H cancers and microsatellite stable (MSS) cancers differently. However, the relationship between MSI and FASN overexpression has not been investigated. Using 976 cases of population-based colorectal cancer samples from 2 large prospective cohort studies, we correlated FASN expression (by immunohistochemistry) with MSI, KRAS and BRAF mutations, p53 expression (by immunohistochemistry), and CIMP status [determined by MethyLight for 8 CIMP-specific gene promoters including CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1]. Marked (2+) FASN overexpression was observed in 110 (11%) of the 976 tumors and was significantly more common in MSI-H tumors (21% [28/135]) than MSI-low (5.6% [4/72], P = .004) and MSS tumors (11% [72/678], P = .001). The association between FASN overexpression and MSI-H persisted even after stratification by CIMP status. In contrast, FASN overexpression was not correlated with CIMP after stratification by MSI status. Fatty acid synthase overexpression was not significantly correlated with sex, tumor location, p53, or KRAS/BRAF status. In conclusion, FASN overexpression in colorectal cancer is associated with MSI-H, independent of CIMP status.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17350669     DOI: 10.1016/j.humpath.2006.11.018

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  28 in total

1.  Quantitation of multiple sphingolipid classes using normal and reversed-phase LC-ESI-MS/MS: comparative profiling of two cell lines.

Authors:  M Athar Masood; Raghavendra P Rao; Jairaj K Acharya; Josip Blonder; Timothy D Veenstra
Journal:  Lipids       Date:  2011-11-29       Impact factor: 1.880

Review 2.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

3.  CIMP and colon cancer gets more complicated.

Authors:  William M Grady
Journal:  Gut       Date:  2007-11       Impact factor: 23.059

Review 4.  Molecular classification and correlates in colorectal cancer.

Authors:  Shuji Ogino; Ajay Goel
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

5.  Commentary: Lifestyle factors and colorectal cancer microsatellite instability--molecular pathological epidemiology science, based on unique tumour principle.

Authors:  Shuji Ogino; Edward Giovannucci
Journal:  Int J Epidemiol       Date:  2012-05-16       Impact factor: 7.196

Review 6.  Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review.

Authors:  Kaori Shima; Katsuhiko Nosho; Yoshifumi Baba; Mami Cantor; Jeffrey A Meyerhardt; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

7.  Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology.

Authors:  Shuji Ogino; Meir Stampfer
Journal:  J Natl Cancer Inst       Date:  2010-03-05       Impact factor: 13.506

8.  Body mass index and risk of colorectal carcinoma subtypes classified by tumor differentiation status.

Authors:  Akiko Hanyuda; Yin Cao; Tsuyoshi Hamada; Jonathan A Nowak; Zhi Rong Qian; Yohei Masugi; Annacarolina da Silva; Li Liu; Keisuke Kosumi; Thing Rinda Soong; Iny Jhun; Kana Wu; Xuehong Zhang; Mingyang Song; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci; Shuji Ogino; Reiko Nishihara
Journal:  Eur J Epidemiol       Date:  2017-05-16       Impact factor: 8.082

9.  Understanding tumor anabolism and patient catabolism in cancer-associated cachexia.

Authors:  Alejandro Schcolnik-Cabrera; Alma Chávez-Blanco; Guadalupe Domínguez-Gómez; Alfonso Dueñas-González
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

10.  Cohort study of fatty acid synthase expression and patient survival in colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Jeffrey A Meyerhardt; Gregory J Kirkner; Andrew T Chan; Takako Kawasaki; Edward L Giovannucci; Massimo Loda; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.